NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of two posters at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal (GI) Cancers Symposium being held January 16-18, 2014 in San Francisco, CA. The posters focus on the potential in GI cancers of lead candidate Selinexor (KPT-330) as well as novel PAK4 inhibitors.
Presentations include:
Safety and Antitumor Activity of Selinexor (KPT-330), a First-In-Class, Oral XPO1 Selective Inhibitor of Nuclear Export: A Phase 1 Study Expanded with Colon Cancer Cohort
- Morten Sorensen, M.D., Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark
- Saturday, January 18, 12:00 PM-2:00 PM, Level One, West Hall
- General Poster Session C and Networking Reception: Cancers of the Colon and Rectum
- Poster Board B45, Abstract #482
Novel PAK4 Inhibitors for Pancreatic Cancer Therapy
- Asfar Azmi, Ph.D., Wayne State University, Detroit, Michigan
- Friday, January 17, 12:00 PM-2:00 PM, Level One, West Hall
- General Poster Session B and Networking Reception: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
- Poster Board B6, Abstract #4233
About Selinexor
Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound that is undergoing Phase 1 studies in patients with advanced hematologic malignancies (NCT01607892), solid tumors (NCT01607905), and sarcomas (NCT01896505). Selinexor functions by binding with the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells.
About Karyopharm
Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with the XPO1, which prevents the export of various proteins out of the nucleus. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's PAK4 inhibitors and SINE compounds, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE compounds, including Selinexor (KPT-330), or any other drug candidate, including PAK4 inhibitors, that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, which is on file with the Securities and Exchange Commission (SEC), and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200
